Gecko Biomedical granted CE Mark approval for its SETALUM Sealant.
M2 PHARMA-September 11, 2017-Gecko Biomedical granted CE Mark approval for its SETALUM Sealant
(C)2017 M2 COMMUNICATIONS
Privately-owned French developer of innovative polymers that support tissue reconstruction, Gecko Biomedical, announced on Monday that it had been granted CE Mark approval for its SETALUM Sealant, which permits the company to market the technology in Europe.
The SETALUM Sealant is a biocompatible, bioresorbable and on-demand activated sealant that can be used in both wet and dynamic environments as an addition to sutures during vascular surgery.
The polymer works by being applied to tissue in-situ, and then triggered using a proprietary light activation pen. The technology was originally developed by the Massachusetts Institute of Technology, Harvard Medical School, and Brigham and Women's Hospital.
Christophe Bancel, Gecko's CEO, commented: "We are delighted to receive the CE Mark for our first product, SETALUM Sealant, as this will allow us to bring new and innovative solutions to the market to improve patient care.
"As a result, we are now ramping up our manufacturing capabilities and selection of strategic partners to bring this innovation to patients."
((Comments on this story may be sent to firstname.lastname@example.org))